Insights On CONTRACT PHARMA MANUFACTURING

  1. PCI Pharma Services Capacity Update July 2025: Fill/Finish 7/28/2025

    PCI is positioned to meet the future of sterile pharmaceutical development and manufacturing with cutting-edge technology, and innovative solutions for high-value biologics, complex formulations, and lyophilized drug products.

  2. Novartis Contract Manufacturing Capacity Update July 2025: Fill/Finish 7/28/2025

    Novartis Contract Manufacturing introduces their fill and finish solutions and capacity. Explore an overview of the aseptic network of Novartis and the capabilities of each site.

  3. INCOG BioPharma Services Capacity Update July 2025: Fill/Finish 7/28/2025

    Our balanced framework addresses the unique challenges of sterile manufacturing by integrating risk-based decision making with systematic capacity planning.

  4. Afton Scientific Capacity Update July 2025: Fill/Finish 7/28/2025

    Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth for our partners in the injectable drug product space.

  5. Viralgen Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    As a leading CDMO in AAV manufacturing, Viralgen facilitates rapid transition to cGMP with a proven platform and an impeccable 100% IND success rate. Discover how Viralgen drives industry progress.

  6. Minaris Advanced Therapies Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, Minaris delivers speed, scalability, and reliability to help therapeutic developers bring cures to patients faster.

  7. Excellos Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    Excellos leverages its extensive starting material expertise as a key differentiator. Explore how our deep understanding of partner-sourced raw materials, quality control, and supply chain management creates significant value for our clients.

  8. Andelyn Biosciences Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    Andelyn Biosciences has used our Curator™ adherent platform to manufacture more than 450 Phase 1 and 2 clinical batches, spanning over 17 years and covering a variety of serotypes and indications.

  9. ReciBioPharm Capacity Update July 2025: Analytical Services 7/28/2025

    ReciBioPharm’s specialized CDMO capabilities include development and manufacture for new biological modalities. Discover the benefits of choosing a CDMO with complete end-to-end services and in-house analytical capabilities.

  10. Building Better CDMO Supply Chain Readiness 7/28/2025

    As advanced therapies grow more complex, CDMOs must move beyond fragmented logistics and embrace integrated supply chain partnerships to ensure scalability, compliance, and long-term success.